Prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) were loaded onto exosomal membranes by fusing them to the lactadherin protein, which increases the antigenicity of PSA, enhances the immune response to PAP in mice with prostate cancer, and improves the anti-tumor effect. The gene discussed is ACP3; the disease is prostate carcinoma.